Cargando…

Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study

BACKGROUND: The bypassing agent, activated prothrombin complex concentrate [aPCC, FEIBA (factor VIII inhibitor bypass activity); Baxalta US Inc, a Takeda company, Lexington, MA, USA], is indicated for the treatment of bleeding episodes, perioperative management, and routine prophylaxis in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ettingshausen, Carmen Escuriola, Hermans, Cedric, Holme, Pål A., Cid, Ana R., Khair, Kate, Oldenburg, Johannes, Négrier, Claude, Botha, Jaco, Lelli, Aurelia, Windyga, Jerzy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387704/ https://www.ncbi.nlm.nih.gov/pubmed/37529276 http://dx.doi.org/10.1177/20406207231184323

Ejemplares similares

Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors
por: Tjønnfjord, Geir E, et al.
Publicado: (2007)

Combination of Novoseven and Feiba in Hemophiliac Patients with Inhibitors
por: Malkan, Umit Yavuz, et al.
Publicado: (2018)

Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate)
por: Negrier, Claude, et al.
Publicado: (2016)

Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors
por: Antunes, S V, et al.
Publicado: (2014)

Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies
por: Ibarra, Francisco, et al.
Publicado: (2022)

Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
por: Wójcik, Cezary, et al.
Publicado: (2009)

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran
por: Golestani, Mina, et al.
Publicado: (2016)

Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial
por: Sera, Valerie A., et al.
Publicado: (2021)

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
por: Dargaud, Yesim, et al.
Publicado: (2021)

Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL study
por: Escuriola-Ettingshausen, Carmen, et al.
Publicado: (2023)

Changing paradigms of hemophilia care across larger specialized treatment centers in the European region
por: Windyga, Jerzy, et al.
Publicado: (2022)

Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE)
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2021)

First experience of a hemophilia monitoring platform: florio HAEMO
por: Zapotocka, Ester, et al.
Publicado: (2022)

octanate(®): over 20 years of clinical experience in overcoming challenges in haemophilia A treatment
por: Klukowska, Anna, et al.
Publicado: (2020)

Living with a “hemophilia‐free mind” – The new ambition of hemophilia care?
por: Krumb, Evelien, et al.
Publicado: (2021)

Patient selection for hemophilia gene therapy: Real‐life data from a single center
por: Krumb, Evelien, et al.
Publicado: (2021)

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2019)

Final Results of the Prospective ADVATE(®) Immune Tolerance Induction Registry (PAIR) Study with Plasma- and Albumin-Free Recombinant Factor VIII
por: Shapiro, Amy D, et al.
Publicado: (2021)

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
por: Carcao, Manuel, et al.
Publicado: (2019)

Thrombosis and Hemophilia: Little More Evidence, Much More Guidance
por: Hermans, Cedric
Publicado: (2023)

Disruptive technology and hemophilia care: The multiple impacts of emicizumab
por: Hermans, Cedric, et al.
Publicado: (2021)

Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders
por: Windyga, Jerzy, et al.
Publicado: (2022)

Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A
por: Batorova, Angelika, et al.
Publicado: (2022)

Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study
por: Windyga, Jerzy, et al.
Publicado: (2020)

Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine
por: Hermans, Cedric, et al.
Publicado: (2023)

Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study
por: Simpson, Mindy L, et al.
Publicado: (2019)

Principles of care for acquired hemophilia
por: Dolan, Gerry, et al.
Publicado: (2021)

Absence of Effect of Emicizumab on D-Dimer Concentrations in Adult Patients with Severe Hemophilia A
por: Iarossi, Michael, et al.
Publicado: (2022)

Insights into the Molecular Genetic of Hemophilia A and Hemophilia B: The Relevance of Genetic Testing in Routine Clinical Practice
por: Pezeshkpoor, Behnaz, et al.
Publicado: (2022)

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors
por: Négrier, Claude, et al.
Publicado: (2022)

The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making
por: Wang, Michael, et al.
Publicado: (2022)

Multiple criteria decision analysis for therapeutic innovations in a hemophilia care center: A pilot study of the organizational impact of innovation in hemophilia care management
por: Beny, Karen, et al.
Publicado: (2022)

Pain Experience in Hemophilia Patients: A Hermeneutic Phenomenological Study
por: Rambod, Masoume, et al.
Publicado: (2016)

Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B
por: Windyga, Jerzy, et al.
Publicado: (2020)

Gene Therapy and Hemophilia: Where Do We Go from Here?
por: Bolous, Nancy S, et al.
Publicado: (2022)

Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia
por: Monahan, Paul E., et al.
Publicado: (2021)

Considerations for shared decision management in previously untreated patients with hemophilia A or B
por: Astermark, Jan, et al.
Publicado: (2023)

Successful Management of Acquired Hemophilia A Associated with Bullous Pemphigoid: A Case Report and Review of the Literature
por: Binet, Quentin, et al.
Publicado: (2017)

Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance
por: Schutgens, Roger E.G., et al.
Publicado: (2023)

IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data
por: Escobar, Miguel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ned13io2ip77hsjv13kcjqa23e